electroCore Expands Intellectual Patent Portfolio for nVNS Technology
July 18 2023 - 8:00AM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
medicine and wellness company, today announced the United States
Patent and Trademark Office (USPTO) has issued a patent related to
non-invasive nerve stimulation with mobile devices.
U.S. Patent No. 11,701,515 entitled “Non-Invasive Nerve
Stimulation with Mobile Device” was issued on July 18, 2023, and is
generally related to a system for transcutaneously stimulating a
nerve within a patient whereby the system includes the stimulator
and a mobile device that provides authorization to enable the
stimulator to operate.
“electroCore continues to broaden its intellectual property
portfolio which consists of over 200 patents and patent
applications,” stated Dan Goldberger, Chief Executive Officer of
electroCore. “Over the last few years, electroCore has compiled a
robust patent portfolio covering the use of mobile devices to
operate a nerve stimulator which we look forward to leveraging in
our new suite of products and devices.”
About electroCore, Inc.electroCore, Inc. is a
commercial stage bioelectronic medicine and wellness company
dedicated to improving health through its non-invasive vagus nerve
stimulation (“nVNS”) technology platform. Our focus is the
commercialization of medical devices for the management and
treatment of certain medical conditions and consumer product
offerings utilizing nVNS to promote general wellbeing and human
performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking StatementsThis press release
and other written and oral statements made by representatives of
electroCore may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include, but are not limited to,
statements about electroCore's business prospects and clinical and
product development plans including potential commercial
applications of nVNS via mobile devices; its pipeline or potential
markets for its technologies; the timing, outcome and impact of
regulatory, clinical and commercial developments; the issuance of
U.S. and international patents, including patents related to
non-invasive nerve stimulation with mobile devices, providing
expanded IP coverage; the possibility of future business models,
the potential of nVNS generally and gammaCore in particular and
other statements that are not historical in nature, particularly
those that utilize terminology such as "anticipates," "expects,"
"believes," "intends," other words of similar meaning, derivations
of such words and the use of future dates. Actual results could
differ from those projected in any forward-looking statements due
to numerous factors. Such factors include, among others, the
ability to obtain additional financing necessary to continue
electroCore's business, sales and marketing and product development
plans, the uncertainties inherent in the development of new
products or technologies, the ability to successfully commercialize
gammaCore™, competition in the industry in which electroCore
operates and general market conditions. All forward-looking
statements are made as of the date of this press release, and
electroCore undertakes no obligation to update forward-looking
statements or to update the reasons why actual results could differ
from those projected in the forward-looking statements, except as
required by law. Investors should refer to all information set
forth in this document and should also refer to the disclosure of
risk factors set forth in the reports and other documents
electroCore files with the SEC, available at
www.sec.gov.Contact:ECOR Investor Relations(973)
302-9253investors@electrocore.com
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Jul 2024 to Jul 2024
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Jul 2023 to Jul 2024